Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2positive breast carcinomas

Zoi, I; Karamouzis, MV; Xingi, E; Sarantis, P; Thomaidou, D; Lembessis, P; Theocharis, S; Papavassiliou, AG

Karamouzis, MV; Papavassiliou, AG (reprint author), Natl & Kapodistrian Univ Athens, Mol Oncol Unit, Dept Biol Chem, Sch Med, 75 M Asias St, Athens 11527, Greece.

BREAST CANCER RESEARCH, 2019; 21 (1):

Abstract

Background: ERBB-2 is overexpressed in about 20% of breast cancers (BCs), indicating poor prognosis. The receptor activator of nuclear factor-kappa B ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索